Given the proliferation of cataclysmic predictions about antibiotic resistance, cases of which are estimated to amount to 12 500 per year in France, we herein decided to compare the empirical clinical microbiology data from our institution with estimates and predictions from 10 major international scientific articles and reports. The analysis of 7 years of antibiotic resistance data from 10 bacterial species and genera of clinical interest from our institution identified no deaths that were directly attributable to extremely drug-resistant bacteria. By comparing our observations to the 10 articles and reports studied herein, we concluded that their results lack empirical data. Interventions are urgently needed to significantly reduce both mortality and the healthcare costs associated with bacterial infections, including the implementation of local and national laboratory data-based surveillance systems for the routine surveillance of antibiotic resistance that would be helpful for a better understanding of how to manage antibiotic-resistant bacteria in the future.
In recent decades, major technological improvements have emerged around the world, particularly through the massive spread of the internet. It was recently estimated that of the 7.3 billion human beings worldwide as of June 2016, >3.6 billion (49.5% of the world's population) have access to and actively use the internet (http://www.internetworldstats.com/stats. htm). This impressive development accelerates the sharing of a diverse range of information, including health-related information. One of the main problems associated with this sharing is that individuals can distort or skew the information based on their perceptions and preconceived ideas about a given event, which can create panic among the population [1] . Therefore, the way information is communicated to the public is of critical importance.
In recent years, we have seen the proliferation of cataclysmic predictions about human health that, fortunately, have never fully materialized. These include, in particular, bioterrorism, Creutzfeldt-Jakob disease, severe acute respiratory syndrome (SARS), the H5N1 and H7N9 influenza viruses, Middle East respiratory syndrome (MERS), and Ebola. These infectious threats have killed hundreds or, in some cases, thousands of people, but the death toll remains far from the million deaths per year due to tuberculosis (1.1 million in 2015) [2] , and far from the 29 000 and 15 000 estimated annual deaths due to Clostridium difficile in the United States and Europe, respectively [3, 4] . This disproportional reaction is particularly observable in Table 1 .
The new fear that is currently taking control around the world is antibiotic resistance, and its purportedly huge impact on humans. Over the last decade, resistance to antibiotics has become a new fear, both within the scientific community and in the media, leading to several alarmist reports of the potential inability to treat patients in the future [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] (Table 2) , and as many as 10 million extra human deaths per year by 2050 [9] . This raises the question of whether we urgently need to develop new antibiotics to maintain the efficacy in the treatment of infectious diseases [15] and/or whether these alarmist reports represent the reality of clinical practice.
Given the importance of the issue, the Institut HospitaloUniversitaire Méditerranée Infection (IHU) has implemented its own empirical bacterial antibiotic-resistance surveillance systems [16, 17] to provide a strong foundation for discussions on the subject, rather than being based on predictions deriving from mathematical models that have yet to succeed in predicting the evolution of any other infectious risks [18] [19] [20] . In this investigation, we compare the empirical data available from the IHU bacterial antibiotic-resistance surveillance network with the estimates and predictions from various articles and reports [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] (Table 2) .
EMPIRICAL OBSERVATIONS
The Global Burden of Disease study group recently published a systematic analysis of the number of deaths due to 249 causes of death, in which they identified that the worldwide number of human deaths due to infectious diseases has dramatically decreased from 10.7 million deaths in 2005 to 8.6 million in 2015 [2] . This is in stark contrast to the global fear about the resurgence of infectious diseases. In particular, this study underlines that the number of global deaths due to lower respiratory infections, which were classified as the leading cause of human death in 1990, and which were the third leading cause of human death in 2015, has decreased from 2.8 million deaths in 2005 to 2.7 million in 2015-that is, a 3.6% decrease over the last 10 years [2] . The decrease is even more striking in children <5 years of age, for whom a 36.9% decrease was observed over the same period [2] . Such observations can be partly explained by improved management of the patients in hospital settings, particularly by the screening and isolation strategies that were developed to control specific pathogens such as methicillin-resistant Staphylococcus aureus (MRSA) [21] . However, as previously discussed [21] , other factors have to be considered, in particular the discovery and worldwide spread of antibiotic compounds [15] , which continues to grow, with a 36% increase in the worldwide human consumption of antibiotics between 2000 and 2010 [12] . Thus, one of the best-known positive impacts of antibiotics on human health is the introduction in the 1940s of antituberculosis medicines, which contributed to the dramatic decrease in worldwide prevalence and mortality of tuberculosis [22] . This decrease is still observable today, with a drop from 1. Another example is the impact of penicillin on pneumonia, which was highlighted by a dramatic decrease from 20%-40% to 5% in the worldwide mortality rate for pneumococcal pneumonia over the last 8 decades [12] .
OBSERVATIONS FROM MARSEILLE
The IHU surveillance system network includes 4 automated laboratory data-based surveillance systems: epidemiological surveillance and alert based on microbiological data (EPIMIC), established in 2002 [16] , and the bacterial real-time laboratory-based surveillance system (BALYSES), the Marseille antibiotic resistance surveillance system (MARSS), and the Provence-Alpes-Côte d' Azur surveillance epidemiologic system (PACASurvE), established in 2013 [17, 23] . EPIMIC, BALYSES, and MARSS analyze data produced by the Timone hospital clinical microbiology laboratory on a weekly basis, and PACASurvE analyzes data produced by 214 microbiology laboratories from France's Provence-Alpes-Côte d' Azur (PACA) region on a weekly basis. In combination, these surveillance systems make it possible to monitor the weekly number of patients where >650 bacterial species were isolated from clinical human samples collected and cultured in the 4 Assistance Publique-Hôpitaux de Marseille public hospitals.
Of these surveillance systems, EPIMIC and MARSS monitor weekly bacterial antibiotic resistance profiles (39 antibiotic [21] , emphasizing that the bacterial epidemiology is evolving, particularly through the continuous appearance and disappearance of bacterial clones that are more competitive. This phenomenon has been observed several times in the past, and was recently observed with the appearance and worldwide spread of the Escherichia coli sequence type 131 clone [24] . Our monitoring system has also enabled us to see that the level of resistance to some critical antibiotics (including vancomycin and imipenem) of invasive strains belonging to 11 bacterial species of particular clinical interest (Enterobacter cloacae, Escherichia coli, 
Enterococcus faecalis, Enterococcus faecium, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus agalactiae,
and Streptococcus pneumoniae) did not globally change or even decrease from 2001 to 2015 [15] . All these examples from the surveillance of antibiotic resistance on the local scale clearly demonstrate that the prevalence of resistance of bacteria to any given antibiotic is difficult to predict, as it depends on a multiplicity of biological, genetic, and ecological factors, creating a complex frame with high stochasticity [25] ; therefore, estimates of extra deaths based on such data are highly speculative.
EXTENSIVELY DRUG-RESISTANT BACTERIA AND HUMAN EXTRA DEATHS
Recently, we decided to collect and analyze the results of 7 years of bacterial antibiotic resistance test performed in our clinical microbiology laboratory, to determine the true impact of extensively drug-resistant (XDR) bacterial strains (ie, bacterial strains susceptible to <2 generic antibiotic compounds) on the mortality of patients hospitalized in our facility (representing 1% of patients hospitalized in France). We focused our analysis on 10 bacterial species and genera of particular interest. Overall, we identified that 27 681 nonredundant bacterial infections due to the bacterial species of interest occurred over the study period, with 37 bacterial strains that were truly XDR. We then checked whether the 37 patients infected by the 37 XDR strains died in the 30 days following the infection. From this, we identified only 4 patients who met the criteria of inclusion. Looking their medical history in detail, we observed that all were admitted in intensive care units with comorbidities (1 for a hemorrhagic cerebellar stroke, 1 for septic shock, 1 for severe aortic valve endocarditis due to MRSA, and 1 for febrile respiratory distress worsened by cystic fibrosis) and that their deaths were not necessarily attributable to XDR bacterial infections. Although this analysis did not include case-controlled studies, which is a major limitation of our analysis, it allows us to conclude that, in our clinical experience, only 1 death was observed due to an XDR bacterial strain, which occurred in 2002 with an XDR Enterobacter aerogenes that became successively resistant to imipenem then colimycin, but which was still susceptible to gentamicin [26, 27] . The patient eventually died after a 10-week stay in the intensive care unit. The real role of the bacteria in the death of this patient is uncertain, but we certainly reached a therapeutic impasse of sorts and the patient died. In the literature, studies describing human deaths due to therapeutic impasses are scarce. Moreover, even in these cases, it is not clear whether or not the clinicians tested second-line antibiotics to treat the bacterial infections, as several useful antibiotics are no longer available [28] , although they are effective against multidrug-resistant (MDR) bacteria [29] . One of the most striking examples of such efficacy is the successful use of antileprosy drugs in combination with other drugs to treat patients with pulmonary tuberculosis due to an XDR Mycobacterium tuberculosis strain [30] . Taken together, these observations clearly demonstrate that the relationship between XDR bacterial infections and mortality is difficult to determine, and that further analysis is needed to clarify this relationship.
WHAT SHOULD WE MAKE OF THE ALARMING ESTIMATES AND PREDICTIONS ABOUT ANTIBIOTIC RESISTANCE?
Comparing our observations to the estimates and predictions from the articles and reports mentioned in Table 2 [ [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] , it is clear that authors are not analyzing true clinical microbiology data. Thus, estimates of the number of extra deaths due to MDR bacterial infections are based solely on mathematical models and formulae. In any case, the real number of deaths attributable to MDR bacteria can be counted, as such data could easily be retrieved from hospital settings. Moreover, each of these reports uses a different definition of MDR bacteria, and the attributability of deaths to those bacteria were not analyzed. Thus, the alarmist messages presented in these reports usually concern 1 bacterial species for a given antibiotic (eg, resistance to carbapenems or colistin in gram-negative bacteria), rather than resistance to a panel of antibiotics from different classes [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] .
CONCLUSIONS AND PERSPECTIVES
Although clinical microbiology data and the results obtained from our analysis can be biased for several reasons, including the way data are extracted and analyzed and the fact that the bacterial epidemiology may vary from one place to another place, the local antibiotic resistance surveillance systems we have implemented in our institution, combined with our strategy to test a large panel of antibiotics, including older antibiotics against MDR bacteria, and the count of deaths associated with XDR, have enabled us to demonstrate that the current fears and alarmist reports both in the scientific community and in the media might be far removed from reality. The difference between our data and the estimates and predictions from the studied articles and reports [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] (Table 2) clearly raises the question of the usefulness of these predictive mathematical models and the quality of data that have been used to build them, as compared to empirical counting and observation of the realities on the ground. Indeed, modeling extra deaths using deductive models without actually counting the real number of deaths attributable to MDR bacteria does not reflect reality, and cannot be used as a standard, because there are many counfounding factors, such as emergence of new bacterial clones, comorbidities, local epidemiology, the availability of drugs, etc. Thus, it is impossible to predict the number of extra deaths based on exceedingly simple mathematical models when there are so many uncontrolled factors [31] . This is illustrated fairly well by Alice's living croquet theory [32] , borrowed from Lewis Carroll's game of "living croquet, " where the mallets are live pink flamingoes and the balls are live hedgehogs who behave unpredictably, making it impossible to predict the outcome of the game. It is the same with predicting extra deaths attributable to bacterial infections due to MDR bacteria, because trends of resistance to antibiotics are unpredictable, and many additional factors are currently unknown or misunderstood. This raises the question of what can be done. In the past, some antibiotics, such as imipenem, were considered to be a "magic bullet, " explaining their overuse for decades. However, the recent emergence of carbapenemase-producing bacteria should prompt us to reconsider old drugs. Considering that it is still unclear how antibiotic-resistant bacterial infection impacts hospitalized patients, we believe that it is reasonable to recommend (1) the adaptation of empirical therapeutic treatments to local antibiotic-resistance epidemiology; (2) the implementation of antibiotic stewardship to guarantee best therapeutic usage; (3) the revival of our historical armamentarium of antibiotics, including those that are no longer distributed by drug companies; (4) the management of patients with bacterial infections in infectious diseases units in coordination with clinical microbiologists; and (5) the implementation of laboratory data-based surveillance systems for the routine surveillance of antibiotic resistance. Such approaches have already been implemented in our institute in its role as an experimental research hospital to fight bacterial infections, including infections due to MDR bacteria. The results from these ongoing approaches to patients with MDR bacterial infections will help us better understand how to manage such patients in the future. 
